NBF-006 is under clinical development by Nitto BioPharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NBF-006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NBF-006 overview

NBF-006 is under development for the treatment of non-small cell lung cancer, metastatic pancreatic cancer and metastatic colorectal cancer. It is a lyophilized lipid nanoparticle (LNP) formulation which delivers encapsulated small interfering ribonucleic acid (siRNA) against of glutathione-S-transferase P. The drug candidate is developed based on siRNA technology. It is administered through intravenous route.

Nitto BioPharma overview

Nitto BioPharma is the US-based developer of life transforming therapies to treat unmet medical needs. It offers unique drug and siRNA delivery solutions. The drug delivery solutions are designed through biodegradable delivery vehicles. The company developed a treatment for liver fibrosis and cirrhosis by using molecular targeting Drug Delivery Systems (DDS). The LNP delivery system offers Biocompatible, biodegradable, non-immunogenic, non-hemolytic, and well tolerated process to target tumors with high specificity. Nitto BioPharma is headquartered in California, the US.

For a complete picture of NBF-006’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.